Allurion Technologies Inc. (ALUR)
NYSE: ALUR · Real-Time Price · USD
2.380
-0.060 (-2.46%)
At close: Mar 14, 2025, 4:00 PM
2.098
-0.282 (-11.84%)
Pre-market: Mar 17, 2025, 4:48 AM EDT
Company Description
Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight.
Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite.
Allurion Technologies Inc. is headquartered in Natick, Massachusetts.
Allurion Technologies Inc.
| Country | United States |
| Founded | 2009 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 504 |
| CEO | Shantanu Gaur |
Contact Details
Address: 11 Huron Drive Natick, Massachusetts 01760 United States | |
| Phone | 508 647 4000 |
| Website | allurion.com |
Stock Details
| Ticker Symbol | ALUR |
| Exchange | NYSE |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001964979 |
| CUSIP Number | 02008G102 |
| ISIN Number | US02008G1022 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Dr. Shantanu K. Gaur M.D. | Co-Founder, Chief Executive Officer, President, Principal Financial and Accounting Officer and Director |
| Dr. Samuel G. Levy | Co-Founder |
| Dr. Ram Chuttani M.D. | MD, Chief Medical Officer and Founding Partner |
| Ojas A. Buch | Chief Operating Officer |
| Brendan Michael Gibbons J.D. | Chief Legal Officer and Corporate Secretary |
| Matt Wright | Vice President of People |
| Joyce Johnson | Senior Vice President of Regulatory Affairs and Quality Assurance |
| Adrian Wild | Senior Vice President of International Commercial |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 13, 2025 | PRER14A | Filing |
| Feb 28, 2025 | PRE 14A | Other preliminary proxy statements |
| Feb 26, 2025 | SCHEDULE 13G | Filing |
| Feb 24, 2025 | SCHEDULE 13D/A | Filing |
| Feb 21, 2025 | 424B3 | Prospectus |
| Feb 21, 2025 | 424B3 | Prospectus |
| Feb 21, 2025 | 8-K | Current Report |
| Feb 20, 2025 | 424B5 | Filing |
| Feb 14, 2025 | 424B3 | Prospectus |
| Feb 14, 2025 | 424B3 | Prospectus |